Moderna insider Hoge sells 80,575 shares
Moderna President Stephen Hoge exercised options for 152,905 shares and sold 80,575 shares under a Rule 10b5‑1 trading plan over two days in September 2026.
Rhea-AI Filing Summary
Moderna, Inc. (MRNA) reported that President Stephen Hoge exercised stock options and sold a portion of the resulting shares under a pre‑arranged trading plan. On September 14 and 15, 2026 he exercised options for a total of 152,905 shares of common stock at an exercise price of $12.21 per share.
Across those two days, Hoge sold 80,575 shares of common stock in market transactions at weighted average prices of $144.13 and $146.07 per share, with actual sale prices ranging from $143.99 to $146.27. The plan was adopted on June 15, 2026 pursuant to Rule 10b5‑1. He also reports indirect holdings of 4,116 shares through Valhalla, LLC and 151,933 shares held by a family trust, for which he disclaims Section 16 beneficial ownership except for any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
8 txns
Insider
Hoge Stephen
Role
President
Sold
80,575 shs ($11.69M)
Approx. gross sale proceeds
$11.69M
Approx. exercise cost
$1.87M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F5 | 76,452 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 76,452 | $12.21 | $933K |
| Sale | Common Stock F1, F3 | 40,281 | $146.07 | $5.88M |
| Exercise | Stock Option (Right to Buy) F1, F5 | 76,453 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 76,453 | $12.21 | $933K |
| Sale | Common Stock F1, F2 | 40,294 | $144.13 | $5.81M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock F4 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 305,810 contracts (Direct);
Common Stock — 1,562,029 shares (Direct);
Common Stock — 4,116 shares (Indirect, By Valhalla, LLC);
Common Stock — 151,933 shares (Indirect, By Trust)
Footnotes (5)
- F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026.
- F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.99 to $144.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.97 to $146.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- F4. These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
- F5. This option is fully vested and exercisable.
Key Figures
Options exercised: 152,905 shares
Shares sold: 80,575 shares
Option exercise price: $12.21 per share
+4 more
7 metrics
Options exercised
152,905 shares
Total common shares underlying options exercised on September 14–15, 2026
Shares sold
80,575 shares
Total Moderna common shares sold on September 14–15, 2026
Option exercise price
$12.21 per share
Exercise price for the stock options converted into 152,905 common shares
Weighted average sale price (Sept 14, 2026)
$144.13 per share
Common stock sold at prices ranging from $143.99 to $144.66
Weighted average sale price (Sept 15, 2026)
$146.07 per share
Common stock sold at prices ranging from $145.97 to $146.27
Indirect holdings via Valhalla, LLC
4,116 shares
Common stock held indirectly as of September 14, 2026
Indirect holdings via family trust
151,933 shares
Trust for spouse and children; beneficial ownership disclaimed except pecuniary interest
Key Terms
Rule 10b5-1 trading plan, weighted average price, Section 16 beneficial ownership, pecuniary interest
4 terms
Rule 10b5-1 trading plan regulatory
"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Section 16 beneficial ownership regulatory
"The reporting person disclaims Section 16 beneficial ownership of these securities"
pecuniary interest financial
"except to the extent of his pecuniary interest therein, if any"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Moderna (MRNA) report for Stephen Hoge in this Form 4?
Stephen Hoge exercised stock options for 152,905 shares of Moderna common stock on September 14 and 15, 2026 and sold 80,575 shares in market transactions over those two days, according to the Form 4.
What was the exercise price of the options Stephen Hoge exercised at Moderna (MRNA)?
The options exercised by Stephen Hoge on September 14 and 15, 2026 covered 152,905 shares of Moderna common stock at an exercise price of $12.21 per share. A related footnote states the option was fully vested and exercisable.
Were Stephen Hoge’s Moderna (MRNA) trades made under a Rule 10b5-1 plan?
Yes. A footnote states that the reported transactions were effected pursuant to a Rule 10b5‑1 trading plan adopted on June 15, 2026, indicating the trades were pre‑arranged under that plan.
What indirect Moderna (MRNA) holdings does Stephen Hoge report in this filing?
He reports indirect ownership of 4,116 shares of common stock held by Valhalla, LLC and 151,933 shares held by a trust for his spouse and children. He disclaims Section 16 beneficial ownership of the trust shares except for any pecuniary interest.
AI-generated analysis. How Rhea-AI works. Not financial advice.
